XTalks

OCTOBER 27, 2021

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

XTalks

AUGUST 14, 2024

The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.

Drug Delivery Systems 111

Drug Delivery Systems Dermatology Drug Delivery Antibody 111

Roots Analysis

MARCH 16, 2022

Broad Clinical Trial Landscape. Till date, over 180 clinical studies which primarily include completed, ongoing and planned trials evaluating various clinical research activity related to exosomes and involving nearly 2,392 patients enrolled across different centers / hospitals, have been initiated worldwide.

Marketing 59

Marketing Manufacturing Drug Delivery Drug Delivery Systems 59

Roots Analysis

FEBRUARY 14, 2023

Broad Clinical Trial Landscape Till date, close to 800 clinical studies evaluating various liposome-based therapeutics have been initiated worldwide. Further, the most targeted disease area within oncological disorders is ovarian cancer, with 226 clinical trials registered in the given time period.

Development 52

Development Manufacturing Drug Delivery Systems Contract Manufacturing 52

Delveinsight

NOVEMBER 29, 2020

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv). The company has plans to initiate new trials for the product however not until the second half of 2021.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Broad Clinical Trial Landscape. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

XTalks

AUGUST 30, 2022

Filipe Rodrigues, MD/MSc, Medical Director at Medpace spoke about the modern-day applications of direct CNS administration, including intrathecal, intraparenchymal and ICV delivery. Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. Figure 3 ).

Trials 83

Trials Drug Delivery Drugs Gene 83